The goal of this observational study is to describe the clinical epidemiological characteristics and disease spectrum distribution of newly diagnosed primary lung cancer patients in a real-world setting. The main questions it aims to answer are: What is the current status of lung cancer epidemiology, including age, gender, smoking history, and pathological subtype distribution? How do different lung cancer screening behaviors (e.g., overscreening, underscreening, guideline-concordant, and precision screening) influence the capture rate of the "curative time window" (defined as adenocarcinoma in situ (AIS)/minimally invasive adenocarcinoma (MIA) or pure Ground-Glass Nodules (GGNs) stage)? What are the economic costs and cumulative radiation exposure associated with these different screening patterns? Researchers will compare these screening behavior groups to evaluate the efficacy of the "low-age, low-frequency" screening strategy in capturing early-stage lung cancer. Participants will be asked to: Provide their medical history and detailed records of pre-diagnosis lung cancer screening (including CT scan history). Allow researchers to collect and analyze their clinical, pathological, and radiological data from hospital records and medical databases. Complete a questionnaire regarding their screening history and health-related behaviors.
Study Type
OBSERVATIONAL
Enrollment
5,390
Fudan University Cancer Center
Shanghai, Shanghai Municipality, China
RECRUITINGEpidemiological Characteristics
Distribution of age, gender, smoking history, and pathological subtypes.
Time frame: through study completion, an average of 1 year
Curative Time Window Capture Rate
The proportion of tumors captured at the AIS/MIA or pure GGN stage
Time frame: through study completion, an average of 1 year
Socioeconomic Indicators
This measure assesses the total direct medical costs. Data are collected through a combination of hospital electronic medical records (EMR) and a structured patient questionnaire. Costs include pre-diagnosis examination expenses (e.g., CT scans, consultations) and post-diagnosis treatment expenses (e.g., surgery, hospitalization, systemic therapy), calculated based on standardized clinical billing data.
Time frame: through study completion, an average of 1 year
Cumulative Radiation Dose
Time frame: through study completion, an average of 1 year
Screening Efficacy
This measure evaluates the efficacy of screening behaviors in detecting early-stage lung cancer. Data are derived from hospital clinical databases and a structured patient questionnaire. Key parameters include the frequency of pre-diagnosis CT scans, age at first screening, and pathological stage at diagnosis. The association is assessed using correlation analysis and logistic regression models to compare the capture rate of the "curative time window" (AIS/MIA/pure GGN) across different screening groups.
Time frame: through study completion, an average of 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.